- Determinants of SARS-CoV-2 anti-spike antibody
- 2 levels following BNT162b2 vaccination: cross-
- sectional analysis of 6,000 SIREN study participants
- 5 Ashley David Otter<sup>1\*</sup>, Silvia D'Arcangelo<sup>1</sup>, Heather Whitaker<sup>2</sup>, Jacqueline Hewson<sup>1</sup>,
- 6 Sarah Foulkes<sup>2</sup>, Ana Atti<sup>2</sup>, Michelle Cole<sup>2</sup>, Ezra Linley<sup>3</sup>, Simon Tonge<sup>3</sup>, Nipunadi
- 7 Hettiarachchi<sup>2</sup>, Noshin Sajedi<sup>2</sup>, Davina Calbraith<sup>2</sup>, Chris Norman<sup>4</sup>, Elen de Lacy<sup>5</sup>,
- 8 Lesley Price<sup>6,7</sup>, Sally Stewart<sup>6,7</sup>, Lisa Cromey<sup>8</sup>, Diane Corrigan<sup>8</sup>, **SIREN study**
- 9 **group†**, Cathy Rowe<sup>1</sup>, Colin S Brown<sup>4</sup>, Jasmin Islam<sup>4</sup>, Amanda Semper<sup>1</sup>, Susan
- 10 Hopkins<sup>9</sup>, Victoria Hall<sup>2,9</sup>, Tim Brooks<sup>1</sup>

11

12

22

23

24

- 13 1 UK Health Security Agency, Porton Down, SP4 0JG
- 14 2 UK Health Security Agency, London, NW9 5EQ
- 15 3 UK Health Security Agency, Manchester, M13 9WL
- 16 4 Health and Care Research Wales, Cardiff, CF11 9AB
- 17 5 Public Health Wales, Cardiff, CF10 4BZ
- 18 6 Glasgow Caledonian University, Glasgow, G4 0BA
- 19 7 Public Health Scotland, Edinburgh, EH12 9EB
- 20 8 Public Health Agency Northern Ireland, Belfast, BT2 8BS
- 21 9 UK Health Security Agency, London, SE1 8UG
- 25 \* Corresponding author: Ashley Otter, ashley.otter@ukhsa.gov.uk
- † SIREN study group authors listed within the supplementary material
- 30 Keywords:
- 31 BNTb162b2, vaccination, COVID-19, healthcare workers

**Abstract**: 250/250

 **Background**: Understanding immunological responses to SARS-CoV-2 vaccinations is integral to the management of SARS-CoV-2. We aimed to investigate determinants of antibody response to the BNT162b2 vaccine.

**Methods**: A cross-sectional analysis of anti-spike binding antibodies in serum samples from healthcare workers after one or two doses. Post-vaccination interval was restricted to ≥21 days after dose 1, ≥14 days after dose 2. The primary outcome was anti-S titres with explanatory variables dose, previous infection, dosing interval, age, ethnicity, and comorbidities. Multivariable linear regression was also conducted.

Results: Participants (n=5,871) included 3,989 post-dose 1, 1,882 post-dose 2. In SARS-CoV-2 infection naïve, 99.65% seroconverted after dose 1 and >99.9% seroconverted after dose 2. Geometric mean anti-S titre in the naïve cohort was 75.48 Binding Antibody Units/ml after dose 1, 7,049 BAU/ml after dose 2. Anti-S titres were higher in those with previous infection (2,111 BAU/ml post-dose 1, 16,052 BAU/ml post-dose 2), and increased with time between infection and vaccination: 3 months 1,970 (1,506-2,579) vs 9 months; 13,759 (8,097-23,379). Longer dosing intervals increased antibody response post-dose 2: 11-fold higher with a longer interval (>10 weeks) than those with shorter intervals, across all age-groups. Younger participants had higher mean titres (>2.2-fold higher). Multivariable regression modelling corroborated the above associations, and also found higher titres associated with being female or from an ethnic minority but lower titres among immunocompromised participants.

**Conclusion**: The number of antigen exposures and timing between vaccinations plays a significant role in the magnitude of the post-vaccination antibody response, with implications for long-term protection and post-booster antibody responses.

## Introduction

60

61 62

63 64

65

66

67

68

69

70

71

72

73 74

75

76

77

78

79

80 81

82

83

84

85

86

87

88

89

90

91

92

93 94 Since its emergence in December 2019, SARS-CoV-2 is the largest respiratory virus pandemic this century, resulting in around 505 million COVID-19 cases and over 6.2 million deaths<sup>1</sup>, including 171,396 within the UK<sup>2</sup>. Towards the end of 2020, vaccines against SARS-CoV-2 became available, including the mRNA vaccines (BNT162b2 (Pfizer/BioNTech) and mRNA-1273 (Moderna)), and the chimpanzee adenovirus vectored-vaccine ChAdOx-1 nCoV-19 AZD1222 (Oxford/Astra Zeneca). Whilst single-dose vaccinations have provided some protection from disease in animal models<sup>3</sup> and have demonstrated robust antibody responses<sup>4–6</sup>, data from phase 3 clinical trials of all these vaccines showed highly efficacious protection against severe disease following two vaccine doses, with trial participants demonstrating robust and sustained immunity<sup>6,7</sup>. On the 2<sup>nd</sup> December 2020, the MHRA granted temporary authorisation for the use of the Pfizer/BioNTech mRNA vaccine (BNT162b2, Comirnaty) for use within the UK8 and the first doses were given on the 8th December 20209. Care home residents, those over 80 years of

age and frontline health and social care workers were the primary focus of the initial SARS-CoV-2 vaccine rollout in the UK, with frontline healthcare workers first being offered the BNT162b2 vaccine in December 2020. In line with the evidence from the manufacturer's clinical trials, the vaccine programme initially recommended 3 weeks between the first and second doses of BNT162b27. Faced with a finite supply of vaccines, in January 2021 the Joint Committee on Vaccination and Immunization (JCVI) recommended extending the interval between first and second dose to up to 12 weeks for both the Pfizer and Oxford Astra/Zeneca vaccines, in order to maximise the number of people receiving a first dose and therefore some level of protection against SARS-CoV-2<sup>10,11</sup>.

As of March 2022, 86.2% of the UK population aged over 12 years had received at least two doses, whilst 92.1% had been given at least one dose of a SARS-CoV-2 vaccine<sup>12</sup>. With increases in disease prevalence and the spread of variants of concern (e.g. Delta and Omicron), the vaccines have shown their capability to prevent and protect against severe SARS-CoV-2 disease, but further work is ongoing to understand durability of the immune response, correlates of protection and why some individuals develop COVID-19 even when double vaccinated.

The SARS-CoV-2 Infection and Reinfection EvaluatioN (SIREN) is a longitudinal study of over 44,000 healthcare workers across the UK13-15. Its initial focus was to assess the impact of infection/reinfection on immunity, but it has since been applied to study vaccination responses in detail. The aim of this paper is to analyse the levels of anti-spike binding antibodies and after COVID-19 vaccination and/or SARS-CoV-2 infection, stratified by age, previous infection,

- gender, health conditions, vaccine dose, timing between sample collection and vaccination,
- 96 and dosing interval.

## Methods

## Study design and setting

For this cross-sectional analysis, a convenience sample was drawn from the cohort of healthcare workers enrolled within the SARS-CoV-2 Infection and Reinfection EvaluatioN (SIREN) study¹³-¹⁵. Inclusion and exclusion criteria for the main analysis can be found in the supplementary material (**Supplementary figure 1**). In brief, eligible participants had submitted an enrolment sample (baseline sample) that had been tested using the Roche Elecsys quantitative SARS-CoV-2 anti-spike (S) and semi-quantitative anti-nucleocapsid (N) antibody assays and submitted this after their first or second COVID-19 vaccination, or were anti-N positive and submitted the sample before vaccination. Only participants receiving 1 or 2 doses of BNT162b2 were included, with vaccines other than BNT162b2 or unknown vaccines excluded due to low vaccination numbers (e.g. ChAdOx-1, mRNA-1273). To prevent bias in the data from participants still mounting an antibody response at the time of sampling, only those participants that gave a baseline sample ≥21 days post dose 1 or post-infection, and those ≥14 days post dose 2 were included in the final analysis.

#### **Data sources**

Vaccination data (manufacturer, dates) were obtained via linkage on personal identifiers from national COVID-19 vaccination registries and directly from participants in their study questionnaires. Site test results reported into national laboratory surveillance systems (in England the Second-Generation Surveillance System (SGSS), with equivalent data securely transferred from Northern Ireland, Wales and Scotland) were linked to individuals' personal information provided in the enrolment questionnaire, with testing data updated daily and captured in a SQL SIREN Database. Serology results from standardised antibody testing at the UKHSA SARS-CoV-2 Serosurveillance laboratory were captured in the SIREN database through linkage on unique identifiers. Data from participants with baseline serum samples with confirmatory antibody test results were extracted from the SIREN SQL database.

## **Outcomes**

The primary outcome was anti-S titre using the Roche Elecsys anti-spike (ACOV2 S) assay which specifically targets anti-RBD antibodies, as described elsewhere<sup>4,16</sup>. Samples were considered positive for anti-nucleocapsid and anti-spike antibodies if the results were ≥1.0 COI and ≥0.8 U/mI, respectively. The Roche Elecsys anti-nucleocapsid assay is semi-

quantitative, as described elsewhere<sup>17</sup>, with the presence of anti-nucleocapsid antibodies used as a proxy for probable previous infection in the absence of a previous PCR positive. The Roche anti-spike assay is quantitative, producing results between 0.4 U/ml and 225,000 U/ml, with automatic dilutions performed to achieve sample results within the quantitative range (0.4 to 250 U/ml). The Roche anti-spike assay has been fully calibrated to the NIBSC first WHO International SARS-CoV-2 immunoglobulin standard (NIBSC code 20/136), enabling reporting in binding antibody units (BAU) per ml (BAU/ml), with all analyses here presented as BAU/ml<sup>18</sup>.

## **Explanatory variables**

Participants were characterised according to their previous infection status: 'naïve' (antinucleocapsid negative at baseline and no linked PCR positive results), 'previous infection with PCR+' (anti-N positive at baseline and linked previous SARS-CoV-2 PCR positive result), 'previous infection without PCR+' (no known previous SARS-CoV-2 PCR positive date but presence of anti-nucleocapsid antibodies). Samples from cohorts of participants prevaccination and post-vaccination were used to compare post-vaccination and post-infection antibody titres.

Outcomes were stratified by dosing interval, age, gender, ethnicity and comorbidities. For analysis on existing health conditions, participants were classified into three categories based on data provided within their enrolment questionnaire. Specific health conditions were categorised: immunosuppression (participants with immune system cancer, rheumatology disease, transplant recipients, those with spleen conditions or other autoimmune conditions not listed here), chronic respiratory disease (asthma, chronic obstructive pulmonary disease, or other chronic respiratory diseases), and chronic non-respiratory diseases (diabetes, obesity, chronic-neurological disease, dementia, other cancers, chronic heart disease, chronic kidney disease, liver disease and HIV).

## Statistical analysis

All statistics were performed on log transformed anti-spike antibody values (in BAU/ml), unless otherwise stated, using R (version 4.0.2), with regression analysis performed in STATA (version 14.2). Mean antibody titres are reported as geometric means. Two-sample t-tests were used for comparisons between groups. Normal error multivariable linear regression models were fitted to log antibody levels (separate models for 28+ days post dose 1 and 21+ days post dose 2), including covariates such as days since dose, age group, sex, ethnicity, existing health conditions and for dose 2 only, dosing schedule group. Regression coefficients were exponentiated for interpretation as adjusted geometric mean ratios. The interval in days

between vaccine dose and the baseline SIREN sample was modelled as log linear (i.e. exponential decay on the original scale). All other covariates were categorical.

Ethics

Ethics approval was granted on 22 May 2020 under IRAS ID 284460, Berkshire Research Ethics Committee Approval by HRA and Health and Care Research Wales.

Results

172

179

187

195 196

- A total of 13,002 participants were included in this analysis, 5,871 post vaccination; ≥21 days post-dose 1 (n=3,989) and ≥14 days post-dose 2 (n=1,882), and 7,131 participants who
- provided baseline samples prior to vaccination and had evidence of previous infection. Most
- participants were female (82.25%) and of white ethnicity (86.94%) and were distributed across
- the different regions of England (n=9,007, 69.27%) as well as Wales (n=669, 5.15%), Scotland
- 178 (n=2,860, 22.00%), and Northern Ireland (n=466, 3.58%).
- 180 Cohort assignment was as follows: naïve cohort (post-dose 1: n=2,863; post-dose 2: n=1,523);
- previous infection with PCR+ (post-dose 1: n=571; post-dose 2; n=165); previous infection
- without PCR+ (post-dose 1: n=555; post-dose 2, n=194). Further classification and numbers
- per infection cohort, gender and ethnicity can be found in **Table 1** (with breakdown further
- shown in supplementary table 1). Within the pre-vaccination cohort, participants were similarly
- assigned previous infection with PCR+ (n=1,990) or previous infection without PCR+
- 186 (n=5,141).
- In the naïve cohort 2,853 participants (99.65%) seroconverted after dose 1, with detectable
- anti-spike antibodies (≥0.8 BAU/ml). Of the 10 participants that did not seroconvert post-dose
- 190 1 (0.35%), the median age was 51 years (Range 40 65, IQR 44.5 56.75) and a median of
- 41 days between first vaccination and sample date (Range 24 71, IQR 36.25 46.75). When
- analysing the sera of participants ≥14 days post-dose 2, 1,522/1,523 participants
- seroconverted (99.93%), with only one participant aged in their 50s not seroconverting within
- 194 29 days between dose 2 and the sample date.
  - Previously infected individuals mount a significantly higher anti-spike antibody
- response post-dose 1 and post-dose 2
- 198 Geometric mean levels of anti-spike binding antibody titres post-dose 1 from all naïve
- 199 participants (n=2,863) were 75.48 BAU/ml (95% CI: 72.26 -78.84), whereas significantly
- 200 higher titres were measured in those with previous infection with PCR+ (n=571, 2,111 BAU/ml
- 201 (1,782 2,501); p=<0.0001) and previous infections without PCR+ (n=555, 7,077 BAU/ml
- 202 (6,248 8,016); (p=<0.0001) (Supplementary Figure 2).
- Geometric mean titres post-dose 2 from all naïve participants (n=1,523) were 7,050 BAU/ml
- 205 (6,634 7,491), whilst those with previous infection with PCR+ (n=165) and previous infection
- 206 without PCR+ (n=194) were significantly higher at 16,052 BAU/ml (14,071 18,312,

p=<0.0001) and 17,759 BAU/ml, respectively (15,595 – 20,222, p=<0.0001) (Supplementary Figure 2).

207

208

209

210

211

212

213214

215

216

217

218

219

220

221222

223

224

225226

227

228

229

230

231

232

233234

235236

237

238

239

240

241242

Previous infection results in comparable antibody titres to 1 vaccine dose. In those with previous infection with PCR+, geometric mean antibody titres post-infection were 96.99 BAU/ml (89.53-105) whilst those with previous infection without PCR+ had a geometric mean titre of 81.20 (77.50-85.07), which is highly similar to the naïve group receiving their first dose, with a geometric mean titre of 75.48 (72.26-78.84).

## Age and dosing interval have significant effects on post-vaccination antibody titres

Naïve older participants had significantly lower antibody responses post-dose 1 than younger HCWs (**Figure 2**); there was a ~2-fold decrease between the 25-34 years (115 BAU/ml, 95% CI 105 - 126) and >54 years (55.51 BAU/ml, 95% CI 50.7 - 60.78) age groups (2.03, 95% CI 1.78-2.32). Similarly, a ~2.3-fold decrease was observed between the 25-34 (12,288 BAU/ml; 95% CI 9,140 - 16,520) and >54 years (5,367 BAU/ml, 95% CI 4,691 - 6,140) age groups post-dose 2 (1.63, 95% CI 1.34-1.98). In contrast, those with previous infection, showed no significant differences between any of the age groups post-dose 1 or post-dose 2 (Figure 1).

The geometric mean antibody titres increased with longer intervals between doses, with a 9fold increase after an interval of >10 weeks compared with >2 and <4 weeks, with this trend consistent across all age groups (Table 2). In general, younger participants had significantly higher antibody responses than older participants with the same vaccine interval, with the exception of the >2 and <4-week dose interval (due to low numbers in the <25 and 25-34 age groups) (Table 2). Thus, participants aged >54 years with a dosing interval of >2 and <4 weeks had a geometric mean antibody titre of 1,303 BAU/ml (n= 25, 95% CI 713.28 - 2382), whereas those aged <25 years with a >10 week dosing interval had a geometric mean antibody titre of 21,472 BAU/ml (n= 10, 95% CI 14,435 - 31,940), a ~16.5 fold difference (Table 2). Antibody titres for each of the dosing interval groups were also analysed in relation to the time elapsed between vaccination and sample date, to prevent the data being skewed by sampling bias (Supplementary Table 3 and Supplementary figure 4). Irrespective of whether participants provided a baseline sample 4-5 weeks, 6-7 weeks or 8-9 weeks after their second dose, the significant difference between >2 and <4 weeks and >10 weeks dosing intervals remained, highlighting that the observed difference in antibody titres was due to the dosing interval and not due to sample collection bias.

## Increasing time between previous infection and dose 1 results in increased antibody titres

Those with previous infection without PCR+ had a significantly higher geometric mean (p=<0.0001) anti-spike antibody level post-dose 1 (7,077 BAU/ml) than those with previous infection with PCR+ (2,111 BAU/ml). When further stratifying the previous infection with PCR+ group by time between infection (median; 101 days) and vaccine dose 1, in general, increasing antibody titres were seen with increasing months after infection, up to 6 months and plateauing (3 months; 1,971 (1,506-2,579) vs 9 months; 13,759 (8,098-23,379), p=<0.0001, **Figure3**A). No increase in antibody titre was observed with increasing months between infection and dose 2 (**Figure3**C).

# Multivariable regression models: the impacts of days since dose, age, gender, ethnicity, and prior health conditions on post-vaccination antibody levels

The decline in antibody levels following dose 1 was shallow, with a long half-life of 157.6 days (95% CI 92.1 - 546.2). Following dose 2 the decline was steeper, with a half-life of 45 days (95% CI 34.3 - 67.2). Adjusted geometric mean ratio of responses is shown (**Figure 4**, Supplementary table 2). Age was associated with antibody titres, with significantly higher titres in younger age groups. Female participants were found to have slightly higher antibody titres post-dose 1 (p=<0.001), but post-dose 2, this significance was not seen (p=0.151). Conversely, ethnic minority participants displayed no significant difference in antibody response post-dose 1 (p=0.147), however, they did show a significantly higher antibody response post-dose 2 (p=0.024). No significant difference was observed between any of these groups post-dose 2 in those previously infected, with PCR+ or without PCR+.

In naïve, immunosuppressed participants, antibody titres post-dose 1 and post-dose 2 were significantly lower than in participants with no immunosuppression (post-dose 1; p=0.001, post-dose 2 = p < 0.001) However no significant difference was seen in those with previous infection post-dose 2 (p=0.563). Naïve participants with chronic non-respiratory diseases had a significantly lower antibody titre post-dose 1 (p=0.005), but no significant difference was observed in participants post-dose 2 (p=0.994). Chronic respiratory disease had no impact on post-dose 1 (p=0.566) or post-dose 2 (p=0.512) antibody titres, and similarly no difference was observed post-dose 2 in previously infected participants (p=0.830).




Figure 1: Antibody levels post-dose 1 (left), post-dose 2 (middle) and post-infection (right), split by cohort and age group. Naive - those with no known previous COVID-19 disease (no PCR confirmation or anti-nucleocapsid antibodies at baseline). Previous infection with PCR+ – those with a confirmed PCR positive. Previous infection without PCR+, those with no known PCR positive date, but presence of anti-nucleocapsid antibodies.




Figure 2: Geometric mean anti-spike antibody levels (BAU/ml) of naïve participants post dose 2 split according to dosing interval and age. Mean BAU/ml increases with dosing interval but decreases with age. Only 1 participant was available within the <25 age category and 2-3-week interval group. The circle diameters correspond to the number of participants for each age group at each dosing interval. Error bars shown are 95% CI.




Figure 3: Post-dose 1 and post-dose 2 antibody titres in participants with previous infection (with history of PCR+), stratified by the interval (in months) between infection (PCR positive date) and vaccine dose 1 date (A) and vaccine dose 2 date (C). Mean post-dose 1 titres according to a participant's exposure status post-dose 1 (B) and post-dose 2 (D). Data shows a general trend of increasing post-dose 1 antibody titres up to 6 months between infection and dose 1. Only participants that provided a baseline sample ≥21 days and <71 days (10 weeks) after dose 1, and those that provided a baseline sample ≥14 days and <71 days (10 weeks) after dose 2 were included. PI; previous infection, w/o; without.




Figure 4: Multivariable regression analysis on anti-spike antibody levels, according to age group, dosing interval group, ethnicity, and gender, and also adjusted for days since dose. Data includes those post-dose-1 (≥28 days) and post-dose 2 (≥21 days). Age and dosing interval significantly affect antibody titres. Previous infection was grouped based on history of PCR+ or presence of anti-nucleocapsid antibodies. Due to low numbers, previous infected individuals with 1 vaccine dose were not included in this analysis

**Table 1: Anti-spike antibody titres for the post-vaccination SIREN cohort.** All data is split according to prior infection status (naïve, previous infection without PCR+, or previous infection with PCR+) as well as gender, ethnicity and age. Data are presented as geometric means of the Roche S values (BAU/ml) with 95% CIs. Those categories with less than 5 participants were removed due to high statistical variance.

|   |                         | n=   | Post Dose 1 (>=21 days)        | n=   | Post Dose 2 (>=14 days)         |  |  |
|---|-------------------------|------|--------------------------------|------|---------------------------------|--|--|
| Naive   |                         | 2863 | 75.48 (72.26 - 78.84)          | 1523 | 7,049.76 (6634.3 - 7491.25)     |  |  |
| Gender  | Male                    | 454  | 65.76 (58.62 - 73.76)          | 271  | 6,447.43 (5574.51 - 7457.04)    |  |  |
|   | Female                  | 2406 | 77.48 (73.92 - 81.21)          | 1250 | 7,172.98 (6708.55 - 7669.55)    |  |  |
|   | Other/Prefer not to say | 3    | N/A                            | 2    | N/A                             |  |  |
| Ethnicity   | White                   | 2657 | 75.12 (71.78 - 78.62)          | 1376 | 7,111.25 (6664.14 - 7588.35)    |  |  |
|   | BAME                    | 204  | 80.26 (68.89 - 93.5)           | 146  | 6,496.29 (5505.18 - 7665.82)    |  |  |
|   | Other/Prefer not to say | 2    | N/A                            | 1    | N/A                             |  |  |
|   | <25                     | 76   | 125.07 (108.12 - 144.66)       | 33   | 12,287.78 (9140.08 - 16519.5)   |  |  |
|   | 25-34                   | 548  | 114.91 (105.16 - 125.57)       | 238  | 9,696.5 (8389.91 - 11206.56)    |  |  |
| Age   | 35-44                   | 736  | 80.33 (73.47 - 87.83)          | 397  | 8,170.3 (7343.88 - 9089.71)     |  |  |
|   | 45-54                   | 831  | 66.27 (61.22 - 71.75)          | 495  | 6,313.87 (5662.17 - 7040.59)    |  |  |
|   | >54                     | 672  | 55.51 (50.7 - 60.78)           | 360  | 5,366.81 (4690.7 - 6140.38)     |  |  |
| Previous Infection (Without PCR+, Anti-nucleocapsid positive) |                         | 555  | 7,076.57 (6247.59 - 8015.54)   | 194  | 17,758.50 (15594.98 - 20222.18) |  |  |
| Gender  | Male                    | 104  | 5,768.25 (4053.02 - 8209.36)   | 43   | 20,738.96 (16574.49 - 25949.79) |  |  |
|   | Female                  | 451  | 7,418.14 (6511.7 - 8450.76)    | 151  | 16,990.98 (14555.7 - 19833.7)   |  |  |
|   | Other/Prefer not to say | 0    | N/A                            | 0    | N/A                             |  |  |
|   | White                   | 487  | 6,964.52 (6067.97 - 7993.53)   | 169  | 17,666.38 (15311.83 - 20383)    |  |  |
| Ethnicity   | BAME                    | 66   | 8,103.88 (6287.82 - 10444.45)  | 25   | 18,393.99 (13517.06 - 25030.5)  |  |  |
|   | Other/Prefer not to say | 2    | N/A                            | 0    | N/A                             |  |  |
| Age   | <25                     | 27   | 10,232.65 (6541.52 - 16006.54) | 8    | 22,227.7 (15374.06 - 32136.63)  |  |  |
|   | 25-34                   | 110  | 6,096.39 (4511.9 - 8237.32)    | 39   | 16,826.71 (13211.03 - 21431.95) |  |  |
|   | 35-44                   | 136  | 5,662.27 (4459.85 - 7188.89)   | 40   | 18,400.62 (14680.29 - 23063.76) |  |  |
|   | 45-54                   | 138  | 7,319.52 (5723.73 - 9360.23)   | 70   | 17,144.67 (12938.13 - 22718.88) |  |  |

| >54                               |                         |     | 8,844.16 (6841.99 - 11432.22) |     | 18,417.3 (14060.62 - 24123.89)  |  |
|-----------------------------------|-------------------------|-----|-------------------------------|-----|---------------------------------|--|
| Previous Infection<br>(With PCR+) |                         | 571 | 2,111.08 (1781.99 - 2500.95)  | 165 | 16,052.39 (14071.49 - 18312.15) |  |
| Gender                            | Male                    | 82  | 2,200.72 (1395.27 - 3471.16)  | 40  | 18,734.58 (14180.51 - 24751.18) |  |
|                                   | Female                  | 487 | 2,108.03 (1754.42 - 2532.9)   | 125 | 15,277.99 (13143.93 - 17758.55) |  |
|                                   | Other/Prefer not to say | 2   | N/A                           | 0   | N/A                             |  |
| Ethnicity                         | White                   | 511 | 2,066.43 (1725.08 - 2475.32)  | 147 | 15,715.86 (13643.01 - 18103.65) |  |
|                                   | BAME                    | 59  | 2,409.72 (1465.83 - 3961.38)  | 18  | 19,084.72 (13066.95 - 27873.89) |  |
|                                   | Other/Prefer not to say | 1   | N/A                           | 0   | N/A                             |  |
|                                   | <25                     | 12  | 1,913.14 (668.94 - 5471.5)    | 7   | 17,550.23 (13979.59 - 22032.88) |  |
| Age                               | 25-34                   | 108 | 2,410.56 (1691.59 - 3435.1)   | 31  | 14,452.38 (10842.22 - 19264.62) |  |
|                                   | 35-44                   | 151 | 1,714.91 (1231.82 - 2387.46)  | 47  | 16,968.73 (13271.93 - 21695.26) |  |
|                                   | 45-54                   | 182 | 1,979.32 (1460.01 - 2683.34)  | 46  | 15,309.26 (11948.24 - 19615.72) |  |
|                                   | >54                     | 118 | 2,721.44 (1808.12 - 4096.1)   | 34  | 17,126.27 (11820.96 - 24812.63) |  |

|           |       | Dose interval (time between 1 <sup>st</sup> dose and 2 <sup>nd</sup> dose) |                                 |                 |                                  |     |                                   |     |                                    |  |
|-----------|-------|--|---------------------------------|-----------------|----------------------------------|-----|-----------------------------------|-----|------------------------------------|--|
|           |       | >2 and <4 weeks  |                                 | >4 and <7 weeks |                                  | ^   | >7 and <10 weeks                  |     | >10 weeks                          |  |
| Age group |       | n=   | GMC (95% CI)                    | n=              | GMC (95% CI)                     | n=  | GMC (95% CI)                      | n=  | GMC (95% CI)                       |  |
|           | <25   | 1  | 1,540<br>(1540 - 1540)          | 9               | 7,320.66<br>(4076.85 - 13145.47) | 13  | 13,430.99<br>(9117.29 - 19785.62) | 10  | 21,472.12<br>(14435.06 - 31939.72) |  |
|           | 25-34 | 14   | 1,541.01<br>(1089.67 - 2179.29) | 39              | 4,261.08<br>(2962.14 - 6129.62)  | 52  | 11,100<br>(8010.84 - 15380.4)     | 133 | 14,205.57<br>(12350.18 - 16339.69) |  |
|           | 35-44 | 19   | 1,626.8<br>(1196.19 - 2212.42)  | 76              | 3,648.89<br>(3003.64 - 4432.75)  | 85  | 8,994.43<br>(7515.83 - 10763.92)  | 217 | 12,018.95<br>(10531.43 - 13716.58) |  |
|           | 45-54 | 34   | 993.47<br>(778.96 - 1267.07)    | 101             | 2,584.21<br>(2071.11 - 3224.42)  | 103 | 6,267.91<br>(4869.24 - 8068.36)   | 257 | 11,489.2<br>(10455.48 - 12625.12)  |  |
|           | >54   | 25   | 1,303.47<br>(713.28 - 2382)     | 87              | 2,368.84<br>(1893.59 - 2963.37)  | 75  | 6,984.68<br>(5632.33 - 8661.74)   | 173 | 8,862.21<br>(7428 - 10573.33)      |  |

#### Discussion

310

311312

313314

315

316317

318

319

320

321

322

323

324325

326

327

328

329

330331

332

333

334335

336

337338

339

340

341342

343

344

345346

With data from 5,871 well-characterised participants after vaccination and 7,131 after infection, and all tested on the same anti-spike and anti-nucleocapsid assays, this dataset has provided a highly robust, cross-sectional analysis of determinants of the antibody response following vaccination. As this study used a fully quantitative anti-RBD assay reporting in BAU/ml relative to the 1st WHO international SAR-CoV-2 immunoglobulin standard<sup>19</sup>, this enables meaningful comparison of post-vaccination responses in different cohorts and across diverse studies. Our data now offers a benchmark against which to compare results by age (and additional variables) across diverse post-vaccination studies, with comparisons to other major manufacturers available through the HARMONY study. We have shown that antibody response increases with repeated antigenic exposure, with participants with three antigen exposures (infection and then two vaccine doses) having the highest anti-S titres. We observed similar anti-S responses in those with a single antigen exposure, irrespective of whether this was from infection or vaccination. Anti-S titres were much higher after two vaccine doses than infection alone. Timing of second antigen exposure impacted antibody responses in our participants, with longer intervals between successive vaccine doses, or first vaccine dose after infection, associated with an increased antibody response as demonstrated by others<sup>6,20-23</sup>. We also found associations with age and immunosuppression, with higher anti-S titres in younger participants and lower titres in those with immunosuppression.

Other studies have also found higher anti-S titres following two antigen exposures, whether vaccination alone or infection and then a single vaccine dose<sup>4,24–26</sup>, but few have shown that those with prior infection continue to have higher titres than double-vaccinated infection-naïve individuals, suggesting that those with prior infection still benefit from vaccination. This finding of incremental increases in anti-S titre with repeated antigen exposures but then subsequent evidence of waning (and diminished protection from infection six months after vaccination) informed the decision to introduce booster doses in the UK and globally. A greater immune response following longer intervals between vaccine doses has also been reported by others, including T-cell and antibody responses<sup>6,21-23</sup>. Together the evidence supports the decision made in the UK, and subsequently other countries, to delay the interval between doses<sup>27,28</sup>. Our data has also shown a similar effect, with higher anti-S titres with extended intervals between infection and vaccination. It is important to recognise however that within the SIREN cohort we have not observed a corresponding difference in protection against SARS-CoV-2 infection associated with timing of dosing interval<sup>13</sup>. Our data also adds to the literature on lower vaccine responses in older age groups<sup>29–32</sup> and individuals with immunosuppression<sup>33,34</sup>, which should inform continued targeted interventions for these groups. Furthermore, with participants having diverse infection history (Wuhan, Alpha, Delta) we are now looking at the role of prior infection and antigenic imprinting on vaccination responses<sup>35</sup>.

Whilst this analysis involved a large population, enabling us to investigate several explanatory and control for important confounders, as a cross-sectional design, we have not followed-up individuals longitudinally. This means we are unable to assess the durability of antibody response in this analysis. Our data is also limited to anti-S titres and does not provide data on neutralising antibody response<sup>36</sup> or T-cells responses<sup>22</sup> as others have shown. It is also important to recognise that we were unable to investigate important factors such as ethnicity and vaccine type in this analysis given the SIREN cohort is predominately of white ethnicity and received the BNT162b2 vaccine. A longitudinal analysis including neutralising antibody testing is underway investigating responses to booster vaccine doses.

The SIREN cohort continues to provide insights into vaccine effectiveness, vaccine responses, reinfections and now vaccination breakthrough infections. With the waning of immunity and increasing vaccine breakthroughs, this cohort will play an essential part in determining why patients develop vaccine breakthrough infections and determining any potential correlates of protection.

## Conclusion

The SIREN cohort continues to provide insights into vaccine effectiveness, vaccine responses, reinfections and now vaccination breakthrough infections. With the waning of immunity and increasing vaccine breakthroughs, this cohort will play an essential part in determining why patients develop vaccine breakthrough infections and determining any potential correlates of protection.

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401 402 Data availability statement Annotated code for this analysis is available at: (https://github.com/SIREN-study/SARS-CoV-2-Immunity). The metadata for this analysis will be available to researchers through the Health Data Research UK CO-CONNECT platform and available for secondary analysis. **Acknowledgments** We thank all SIREN participants for enrolling within the SIREN study and continuing to provide samples. We also thank all staff within the NHS that enable SIREN to operate. Additionally, we thank the staff and students at UKHSA Porton Down that conducted the sample receipt and testing of baseline SIREN samples. **Author contributions** ADO, VH, SH, HW, TB and AS conceptualised this analysis. ADO wrote the initial manuscript, with input from AS, VH, SF, SH, TB, HW, JH, SD'A and AA. ADO, SD'A, JH, CR, AS and TB oversaw the serological testing. EL and ST are responsible for sample collation, shipping and archiving, with support from JH. HW supported statistical analysis. VH and SH design and lead on the SIREN study. MC, EL, ST, AT-K, NH, NS, DC, IM, CT, CSB and JI support sample receipt, movement of samples and general SIREN operations. **Competing interests** The authors declare no competing interests. **Ethics** This study was registered, number ISRCTN11041050, and received approval from the Berkshire Research Ethics Committee on 22 May 2020 **Funding** The study is funded by the Department for Health and Social Care and UKHSA (formerly PHE), with contributions from the governments of Northern Ireland, Scotland and Wales. Funding was also provided by The National Institute for Health Research (NIHR) as an Urgent Public Health Priority Study and through the Health Protection Research Units. The study was also awarded grant funding from the Medical Research Council (Grant title: Investigation of proven vaccine breakthrough by SARS-CoV-2 variants in established UK healthcare worker cohorts: SIREN consortium & PITCH Plus Pathway). **Grants** 

Grant funding awarded by the MRC in 2021 for the investigation of vaccine breakthroughs

within SIREN and the SIREN consortium (Grant number: MR/W02067X/1)

403

404 405

406

407

408

409

## References

411

- 413 1. John Hopkins University. COVID-19 Dashboard. (2022).
- 414 2. GOV.UK. UK Coronavirus Dashboard. (2022).
- 415 3. Huang, Q. et al. A single-dose mRNA vaccine provides a long-term protection for
- hACE2 transgenic mice from SARS-CoV-2. *Nat. Commun.* **12**, 1–10 (2021).
- 417 4. Manisty, C. et al. Antibody response to first BNT162b2 dose in previously SARS-CoV-
- 418 2-infected individuals. *Lancet* (2021). doi:10.1016/S0140-6736(21)00501-8
- 419 5. Bradley, T. et al. Antibody Responses after a Single Dose of SARS-CoV-2 mRNA
- 420 Vaccine. N. Engl. J. Med. 384, 1959–1961 (2021).
- 421 6. Voysey, M. et al. Single-dose administration and the influence of the timing of the
- booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222)
- vaccine: a pooled analysis of four randomised trials. *Lancet* **397**, 881–891 (2021).
- 424 7. Polack, F. P. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N.
- 425 Engl. J. Med. **383**, 2603–2615 (2020).
- 426 8. Medicines & Healthcare products Regulatory Agency (MHRA). Vaccine BNT162b2 -
- 427 CONDITIONS OF AUTHORISATION UNDER REGULATION 174. (2021).
- 428 9. Medicines & Healthcare products Regulatory Agency (MHRA). Public Assessment
- Report Authorisation for Temporary Supply COVID-19 mRNA Vaccine BNT162b2
- concentrate for solution for injection Department of Health and Social Care (DHSC)
- 431 Pfizer Limited & BioNTech Manufacturing GmbH. 2, 1–74 (2020).
- 432 10. Public Health England. Annex A: Report to JCVI on estimated efficacy of a single
- dose of Pfizer BioNTech (BNT162b2 mRNA) vaccine and of a single dose of
- 434 ChAdOx1 vaccine (AZD1222). (2020).
- 435 11. Public Health England. JCVI issues interim advice on COVID-19 booster vaccination.
- 436 (2021). Available at: https://www.gov.uk/government/news/jcvi-issues-advice-on-the-
- 437 astrazeneca-covid-19-vaccine. (Accessed: 20th October 2021)
- 438 12. Gov.uk. GOV.UK Coronavirus (COVID-19) in the UK. (2021). Available at:
- 439 coronavirus.data.gov.uk.
- 440 13. Hall, V. et al. Protection against SARS-CoV-2 after Covid-19 Vaccination and
- 441 Previous Infection. N. Engl. J. Med. (2022). doi:10.1056/nejmoa2118691
- 442 14. Hall, V. J. et al. COVID-19 vaccine coverage in health-care workers in England and
- effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective,
- 444 multicentre, cohort study. *Lancet (London, England)* 1725–1735 (2021).
- 445 doi:10.1016/S0140-6736(21)00790-X
- Hall, V. J. et al. SARS-CoV-2 infection rates of antibody-positive compared with

- antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). *Lancet* **397**, 1459–1469 (2021).
- Parry, H. *et al.* Differential immunogenicity of BNT162b2 or ChAdOx1 vaccines after
   extended-interval homologous dual vaccination in older people. *Immun. Ageing* 18, 1–
- 451 8 (2021).
- 452 17. Manisty, C. et al. Time series analysis and mechanistic modelling of heterogeneity
- and sero-reversion in antibody responses to mild SARS-CoV-2 infection.
- 454 *EBioMedicine* **65**, 103259 (2021).
- 455 18. Elecsys® Anti-SARS-CoV-2 S. Available at:
- 456 https://diagnostics.roche.com/global/en/products/params/elecsys-anti-sars-cov-2-
- s.html. (Accessed: 12th February 2021)
- 458 19. Kristiansen, P. A. et al. WHO International Standard for anti-SARS-CoV-2
- 459 immunoglobulin. *Lancet* **397**, 1347–1348 (2021).
- 460 20. Tauzin, A. et al. Strong humoral immune responses against SARS-CoV-2 Spike after
- BNT162b2 mRNA vaccination with a sixteen-week interval between doses. *medRxiv*
- 462 2021.09.17.21263532 (2021). doi:10.1101/2021.09.17.21263532
- 21. Parry, H. et al. Extended interval BNT162b2 vaccination enhances peak antibody
- generation in older people. *medRxiv* 2021.05.15.21257017 (2021).
- 465 doi:10.1101/2021.05.15.21257017
- 466 22. Payne, R. P. et al. Immunogenicity of standard and extended dosing intervals of
- 467 BNT162b2 mRNA vaccine. Cell (2021). doi:10.1016/j.cell.2021.10.011
- 468 23. Angyal, A. et al. Articles T-cell and antibody responses to first BNT162b2 vaccine
- dose in previously infected and SARS-CoV-2-naive UK health-care workers: a
- 470 multicentre prospective cohort study. *The Lancet Microbe* (2021). doi:10.1016/S2666-
- 471 5247(21)00275-5
- 472 24. Tré-Hardy, M. et al. Reactogenicity, safety and antibody response, after one and two
- doses of mRNA-1273 in seronegative and seropositive healthcare workers. *Journal of*
- 474 Infection **83**, 237–279 (2021).
- 475 25. Prendecki, M. et al. Effect of previous SARS-CoV-2 infection on humoral and T-cell
- 476 responses to single-dose BNT162b2 vaccine. *The Lancet* **397**, 1178–1181 (2021).
- 477 26. Krammer, F. et al. Antibody Responses in Seropositive Persons after a Single Dose
- 478 of SARS-CoV-2 mRNA Vaccine. N. Engl. J. Med. 384, 1372–1374 (2021).
- 479 27. Joint Committee on Vaccinations and Immunisations. Optimising the COVID-19
- vaccination programme for maximum short-term impact. Updated January 26, 2021.
- 481 January 26 1–5 (2021).
- 482 28. Center for Disease Control and Prevention. Use of COVID-19 Vaccines in the United
- 483 States. Febr. 22 1–3 (2022).

- Wei, J. *et al.* Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom. *Nat. Microbiol.* **6**, 1140–1149 (2021).
- 486 30. Collier, D. A. *et al.* Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. *Nature* **596**, 417–422 (2021).
- 488 31. Subbarao, S. *et al.* Robust antibody responses in 70-80-year-olds 3 weeks after the 489 first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, 490 January to February 2021. *Eurosurveillance* **26**, 1–6 (2021).
- 491 32. Eyre, D. W. *et al.* Quantitative SARS-CoV-2 anti-spike responses to Pfizer–BioNTech 492 and Oxford–AstraZeneca vaccines by previous infection status. *Clin. Microbiol. Infect.* 493 **27**, 1516.e7-1516.e14 (2021).
- 494 33. Kearns, P. *et al.* Examining the Immunological Effects of COVID-19 Vaccination in
   495 Patients with Conditions Potentially Leading to Diminished Immune Response
   496 Capacity The OCTAVE Trial. SSRN Electron. J. 1–25 (2021).
   497 doi:10.2139/ssrn.3910058
- 498 34. Parry, H. *et al.* Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia. *Blood Cancer J.* **11**, 4–11 (2021).
- SARS-CoV-2 variants. *Science (80-. ).* (2021). doi:10.1126/science.abm0811
- 36. Levin, E. G. *et al.* Waning Immune Humoral Response to BNT162b2 Covid-19
   Vaccine over 6 Months. *N. Engl. J. Med.* 1–11 (2021). doi:10.1056/NEJMoa2114583